Global Real World Evidence Solutions Market

Real World Evidence Solutions Comprehensive Study by Application (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data, Others), End-User (Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies, Other), Therapeutic Area (Oncology, Immunology, Neurology, Cardiovascular Disease, Other) Players and Region - Global Market Outlook to 2030

Real World Evidence Solutions Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 14.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Pharmaceutical companies spend a lot of time and money in the pre-authorization drug development stages, particularly in phase-III clinical trials, to provide solid evidence on their products' safety and efficacy. Such experiments are planned as Randomized Controlled Trials (RCTs), which are the gold standard for testing to prove the safety and effectiveness of a product of high validity but within clinical trial's tightly regulated boundaries. RCTs must be supplemented by the controversial new criterion known as Real-World Evidence (RWE). It is scientific evidence derived from real-world data about the use and possible benefits or risks of a medical product. Various research designs or evaluations, including but not limited to randomized trials, including large simple trials, pragmatic trials, and observational studies (prospective and/or retrospective), may produce RWE. It generates insight, foresight, and exploratory observations on diseases, goods, and patient populations using real-world data (RWD).The real-world evidence solution is being used to demonstrate the effectiveness of medications, vaccines, and other types of knowledge evidence. Furthermore, RWE is able to provide evidences based on real-world data. The widespread use of real-world evidence helps to improve healthcare quality, and RWD data on the effectiveness and safety of new drugs and medical devices can supplement RCT data.

Highlights from Real World Evidence Solutions Market Study
AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR14.2%


The key Players profiled in the report are IQVIA (United States), International Business Machines Corporation (IBM)(United States), ICON (Ireland), PAREXEL (United States), Syase (United States), Pharmaceutical Product Development (United States), Optum (United States) and Clinigen Group (United Kingdom). Additionally, other players that are part of this comprehensive study are Palantir Technologies (United Kingdom) and Flatiron Health (United States).

Geographic Breakdown and Segment Analysis
The Global Real World Evidence Solutions market presents a comprehensive analysis of the Real World Evidence Solutions market by end-user/application (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Real World Evidence Solutions industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Real World Evidence Solutions market

Analyst at AMA have segmented the market study of Global Real World Evidence Solutions market by Type, Application and Region.

Influencing Trend:
Delays in Drug Development and the Subsequent Increase in Development Costs

Market Growth Drivers:
Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases and Shift From Volume- to Value-Based Care

Challenges:
Unwillingness to Rely on Real-world Studies

Restraints:
Lack of Universally Accepted Methodological Standards and Data Processing Infrastructure

Opportunities:
Growth Opportunities in Emerging Markets and Rising Focus on End-To-End RWE Services

Market Developments Activities:
In 2021, ICON (Ireland) acquires PRA Health Sciences (USA). The acquisition was conducted to integrate PRA's mobile and connected health platform, real data and information solutions with ICON's network of Accellacare sites, home health services and wearables expertise., In 2020, Cerner (USA) acquires the health division of Kantar Group (UK). With this acquisition, Cerner entered the RWE solutions market. and In 2020, Cegedim Health Data (France) has partnered with Aetion (USA). This partnership was undertaken to integrate Cegedim's THIN - European Real Data into the Aetion Evidence Platform (AEP). AEP analyzes real-world data, including claims, electronic health records, registries, and clinical trial data, to generate transparent, rapid and scientifically validated RWEs for the safety, effectiveness and value of medical interventions.
In 2021, Verantos (USA) has partnered with Lundbeck (USA). Through this partnership, the two companies will collaborate on research to enable RWE to support migraine treatment., In 2021, Five RWD and analytics organizations have joined an industry coalition dedicated to advancing the use of RWE to support regulatory decisions. The founding members of the RWE Alliance are Aetion, Flatiron Health, IQVIA, Syapse and Tempus. and May 2020 – Syapse, a San Francisco, CA-based provider of precision oncology solutions announced USD 30 million in new equity funding to accelerate the creation and use of real-world evidence (RWE) in oncology led by Revelation Alpine, LLC.



The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Target Audience
Hospitals and clinics, Pharmaceutical and Medical Device Manufacturing Companies, Academic Medical Centers, Government Research Organizations, Contract Research Organizations, Research and Consulting Firms and Regulatory Agencies

Report Objectives / Segmentation Covered

By Application
  • Claims Data
  • Clinical Settings Data
  • Patient-Powered Data
  • Pharmacy Data
  • Others
By End-User
  • Healthcare Payers
  • Healthcare Providers
  • Pharmaceutical & Medical Device Companies
  • Other

By Therapeutic Area
  • Oncology
  • Immunology
  • Neurology
  • Cardiovascular Disease
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases
      • 3.2.2. Shift From Volume- to Value-Based Care
    • 3.3. Market Challenges
      • 3.3.1. Unwillingness to Rely on Real-world Studies
    • 3.4. Market Trends
      • 3.4.1. Delays in Drug Development and the Subsequent Increase in Development Costs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Real World Evidence Solutions, by Application, End-User, Therapeutic Area and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Real World Evidence Solutions (Value)
      • 5.2.1. Global Real World Evidence Solutions by: Application (Value)
        • 5.2.1.1. Claims Data
        • 5.2.1.2. Clinical Settings Data
        • 5.2.1.3. Patient-Powered Data
        • 5.2.1.4. Pharmacy Data
        • 5.2.1.5. Others
      • 5.2.2. Global Real World Evidence Solutions by: End-User (Value)
        • 5.2.2.1. Healthcare Payers
        • 5.2.2.2. Healthcare Providers
        • 5.2.2.3. Pharmaceutical & Medical Device Companies
        • 5.2.2.4. Other
      • 5.2.3. Global Real World Evidence Solutions by: Therapeutic Area (Value)
        • 5.2.3.1. Oncology
        • 5.2.3.2. Immunology
        • 5.2.3.3. Neurology
        • 5.2.3.4. Cardiovascular Disease
        • 5.2.3.5. Other
      • 5.2.4. Global Real World Evidence Solutions Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Real World Evidence Solutions: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. IQVIA (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. International Business Machines Corporation (IBM)(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ICON (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. PAREXEL (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Syase (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pharmaceutical Product Development (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Optum (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Clinigen Group (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Real World Evidence Solutions Sale, by Application, End-User, Therapeutic Area and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Real World Evidence Solutions (Value)
      • 7.2.1. Global Real World Evidence Solutions by: Application (Value)
        • 7.2.1.1. Claims Data
        • 7.2.1.2. Clinical Settings Data
        • 7.2.1.3. Patient-Powered Data
        • 7.2.1.4. Pharmacy Data
        • 7.2.1.5. Others
      • 7.2.2. Global Real World Evidence Solutions by: End-User (Value)
        • 7.2.2.1. Healthcare Payers
        • 7.2.2.2. Healthcare Providers
        • 7.2.2.3. Pharmaceutical & Medical Device Companies
        • 7.2.2.4. Other
      • 7.2.3. Global Real World Evidence Solutions by: Therapeutic Area (Value)
        • 7.2.3.1. Oncology
        • 7.2.3.2. Immunology
        • 7.2.3.3. Neurology
        • 7.2.3.4. Cardiovascular Disease
        • 7.2.3.5. Other
      • 7.2.4. Global Real World Evidence Solutions Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Real World Evidence Solutions: by Application(USD Million)
  • Table 2. Real World Evidence Solutions Claims Data , by Region USD Million (2018-2023)
  • Table 3. Real World Evidence Solutions Clinical Settings Data , by Region USD Million (2018-2023)
  • Table 4. Real World Evidence Solutions Patient-Powered Data , by Region USD Million (2018-2023)
  • Table 5. Real World Evidence Solutions Pharmacy Data , by Region USD Million (2018-2023)
  • Table 6. Real World Evidence Solutions Others , by Region USD Million (2018-2023)
  • Table 7. Real World Evidence Solutions: by End-User(USD Million)
  • Table 8. Real World Evidence Solutions Healthcare Payers , by Region USD Million (2018-2023)
  • Table 9. Real World Evidence Solutions Healthcare Providers , by Region USD Million (2018-2023)
  • Table 10. Real World Evidence Solutions Pharmaceutical & Medical Device Companies , by Region USD Million (2018-2023)
  • Table 11. Real World Evidence Solutions Other , by Region USD Million (2018-2023)
  • Table 12. Real World Evidence Solutions: by Therapeutic Area(USD Million)
  • Table 13. Real World Evidence Solutions Oncology , by Region USD Million (2018-2023)
  • Table 14. Real World Evidence Solutions Immunology , by Region USD Million (2018-2023)
  • Table 15. Real World Evidence Solutions Neurology , by Region USD Million (2018-2023)
  • Table 16. Real World Evidence Solutions Cardiovascular Disease , by Region USD Million (2018-2023)
  • Table 17. Real World Evidence Solutions Other , by Region USD Million (2018-2023)
  • Table 18. South America Real World Evidence Solutions, by Country USD Million (2018-2023)
  • Table 19. South America Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 20. South America Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 21. South America Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 22. Brazil Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 23. Brazil Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 24. Brazil Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 25. Argentina Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 26. Argentina Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 27. Argentina Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 28. Rest of South America Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 30. Rest of South America Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 31. Asia Pacific Real World Evidence Solutions, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 33. Asia Pacific Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 34. Asia Pacific Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 35. China Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 36. China Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 37. China Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 38. Japan Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 39. Japan Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 40. Japan Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 41. India Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 42. India Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 43. India Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 44. South Korea Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 45. South Korea Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 46. South Korea Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 47. Taiwan Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 48. Taiwan Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 49. Taiwan Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 50. Australia Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 51. Australia Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 52. Australia Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 56. Europe Real World Evidence Solutions, by Country USD Million (2018-2023)
  • Table 57. Europe Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 58. Europe Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 59. Europe Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 60. Germany Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 61. Germany Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 62. Germany Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 63. France Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 64. France Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 65. France Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 66. Italy Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 67. Italy Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 68. Italy Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 69. United Kingdom Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 70. United Kingdom Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 71. United Kingdom Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 72. Netherlands Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 73. Netherlands Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 74. Netherlands Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 75. Rest of Europe Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 76. Rest of Europe Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 77. Rest of Europe Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 78. MEA Real World Evidence Solutions, by Country USD Million (2018-2023)
  • Table 79. MEA Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 80. MEA Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 81. MEA Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 82. Middle East Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 83. Middle East Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 84. Middle East Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 85. Africa Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 86. Africa Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 87. Africa Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 88. North America Real World Evidence Solutions, by Country USD Million (2018-2023)
  • Table 89. North America Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 90. North America Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 91. North America Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 92. United States Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 93. United States Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 94. United States Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 95. Canada Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 96. Canada Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 97. Canada Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 98. Mexico Real World Evidence Solutions, by Application USD Million (2018-2023)
  • Table 99. Mexico Real World Evidence Solutions, by End-User USD Million (2018-2023)
  • Table 100. Mexico Real World Evidence Solutions, by Therapeutic Area USD Million (2018-2023)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Real World Evidence Solutions: by Application(USD Million)
  • Table 110. Real World Evidence Solutions Claims Data , by Region USD Million (2025-2030)
  • Table 111. Real World Evidence Solutions Clinical Settings Data , by Region USD Million (2025-2030)
  • Table 112. Real World Evidence Solutions Patient-Powered Data , by Region USD Million (2025-2030)
  • Table 113. Real World Evidence Solutions Pharmacy Data , by Region USD Million (2025-2030)
  • Table 114. Real World Evidence Solutions Others , by Region USD Million (2025-2030)
  • Table 115. Real World Evidence Solutions: by End-User(USD Million)
  • Table 116. Real World Evidence Solutions Healthcare Payers , by Region USD Million (2025-2030)
  • Table 117. Real World Evidence Solutions Healthcare Providers , by Region USD Million (2025-2030)
  • Table 118. Real World Evidence Solutions Pharmaceutical & Medical Device Companies , by Region USD Million (2025-2030)
  • Table 119. Real World Evidence Solutions Other , by Region USD Million (2025-2030)
  • Table 120. Real World Evidence Solutions: by Therapeutic Area(USD Million)
  • Table 121. Real World Evidence Solutions Oncology , by Region USD Million (2025-2030)
  • Table 122. Real World Evidence Solutions Immunology , by Region USD Million (2025-2030)
  • Table 123. Real World Evidence Solutions Neurology , by Region USD Million (2025-2030)
  • Table 124. Real World Evidence Solutions Cardiovascular Disease , by Region USD Million (2025-2030)
  • Table 125. Real World Evidence Solutions Other , by Region USD Million (2025-2030)
  • Table 126. South America Real World Evidence Solutions, by Country USD Million (2025-2030)
  • Table 127. South America Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 128. South America Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 129. South America Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 130. Brazil Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 131. Brazil Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 132. Brazil Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 133. Argentina Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 134. Argentina Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 135. Argentina Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 136. Rest of South America Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 137. Rest of South America Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 138. Rest of South America Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 139. Asia Pacific Real World Evidence Solutions, by Country USD Million (2025-2030)
  • Table 140. Asia Pacific Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 141. Asia Pacific Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 142. Asia Pacific Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 143. China Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 144. China Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 145. China Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 146. Japan Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 147. Japan Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 148. Japan Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 149. India Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 150. India Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 151. India Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 152. South Korea Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 153. South Korea Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 154. South Korea Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 155. Taiwan Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 156. Taiwan Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 157. Taiwan Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 158. Australia Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 159. Australia Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 160. Australia Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 164. Europe Real World Evidence Solutions, by Country USD Million (2025-2030)
  • Table 165. Europe Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 166. Europe Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 167. Europe Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 168. Germany Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 169. Germany Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 170. Germany Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 171. France Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 172. France Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 173. France Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 174. Italy Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 175. Italy Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 176. Italy Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 177. United Kingdom Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 178. United Kingdom Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 179. United Kingdom Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 180. Netherlands Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 181. Netherlands Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 182. Netherlands Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 183. Rest of Europe Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 184. Rest of Europe Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 185. Rest of Europe Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 186. MEA Real World Evidence Solutions, by Country USD Million (2025-2030)
  • Table 187. MEA Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 188. MEA Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 189. MEA Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 190. Middle East Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 191. Middle East Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 192. Middle East Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 193. Africa Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 194. Africa Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 195. Africa Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 196. North America Real World Evidence Solutions, by Country USD Million (2025-2030)
  • Table 197. North America Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 198. North America Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 199. North America Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 200. United States Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 201. United States Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 202. United States Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 203. Canada Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 204. Canada Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 205. Canada Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 206. Mexico Real World Evidence Solutions, by Application USD Million (2025-2030)
  • Table 207. Mexico Real World Evidence Solutions, by End-User USD Million (2025-2030)
  • Table 208. Mexico Real World Evidence Solutions, by Therapeutic Area USD Million (2025-2030)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Real World Evidence Solutions: by Application USD Million (2018-2023)
  • Figure 5. Global Real World Evidence Solutions: by End-User USD Million (2018-2023)
  • Figure 6. Global Real World Evidence Solutions: by Therapeutic Area USD Million (2018-2023)
  • Figure 7. South America Real World Evidence Solutions Share (%), by Country
  • Figure 8. Asia Pacific Real World Evidence Solutions Share (%), by Country
  • Figure 9. Europe Real World Evidence Solutions Share (%), by Country
  • Figure 10. MEA Real World Evidence Solutions Share (%), by Country
  • Figure 11. North America Real World Evidence Solutions Share (%), by Country
  • Figure 12. Global Real World Evidence Solutions share by Players 2023 (%)
  • Figure 13. Global Real World Evidence Solutions share by Players (Top 3) 2023(%)
  • Figure 14. Global Real World Evidence Solutions share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. IQVIA (United States) Revenue, Net Income and Gross profit
  • Figure 17. IQVIA (United States) Revenue: by Geography 2023
  • Figure 18. International Business Machines Corporation (IBM)(United States) Revenue, Net Income and Gross profit
  • Figure 19. International Business Machines Corporation (IBM)(United States) Revenue: by Geography 2023
  • Figure 20. ICON (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. ICON (Ireland) Revenue: by Geography 2023
  • Figure 22. PAREXEL (United States) Revenue, Net Income and Gross profit
  • Figure 23. PAREXEL (United States) Revenue: by Geography 2023
  • Figure 24. Syase (United States) Revenue, Net Income and Gross profit
  • Figure 25. Syase (United States) Revenue: by Geography 2023
  • Figure 26. Pharmaceutical Product Development (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pharmaceutical Product Development (United States) Revenue: by Geography 2023
  • Figure 28. Optum (United States) Revenue, Net Income and Gross profit
  • Figure 29. Optum (United States) Revenue: by Geography 2023
  • Figure 30. Clinigen Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Clinigen Group (United Kingdom) Revenue: by Geography 2023
  • Figure 32. Global Real World Evidence Solutions: by Application USD Million (2025-2030)
  • Figure 33. Global Real World Evidence Solutions: by End-User USD Million (2025-2030)
  • Figure 34. Global Real World Evidence Solutions: by Therapeutic Area USD Million (2025-2030)
  • Figure 35. South America Real World Evidence Solutions Share (%), by Country
  • Figure 36. Asia Pacific Real World Evidence Solutions Share (%), by Country
  • Figure 37. Europe Real World Evidence Solutions Share (%), by Country
  • Figure 38. MEA Real World Evidence Solutions Share (%), by Country
  • Figure 39. North America Real World Evidence Solutions Share (%), by Country
List of companies from research coverage that are profiled in the study
  • IQVIA (United States)
  • International Business Machines Corporation (IBM)(United States)
  • ICON (Ireland)
  • PAREXEL (United States)
  • Syase (United States)
  • Pharmaceutical Product Development (United States)
  • Optum (United States)
  • Clinigen Group (United Kingdom)
Additional players considered in the study are as follows:
Palantir Technologies (United Kingdom) , Flatiron Health (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 159 Pages 93 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Real World Evidence Solutions Market Quantitative research analysis
Global Real World Evidence Solutions Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2030
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Unwillingness to Rely on Real-world Studies

Know More About Global Real World Evidence Solutions Market Report?

Have a Query? Click Here

Other Related Reports

Wearable Artificial Kidney Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Dialysis Centers, Others), Components (Dialysis Membrane, Dialysate Regeneration, Vascular Acces...
$ 3650
Isothermal amplification Comprehensive Study by Type (Instruments, Reagents), Application (Blood Screening, Infectious Disease Diagnosis, Other), Technology (TMA, LAMP, SDA, HDA, NASBA, Others), End ...
$ 3350
Healthcare IT (HIT) - Comprehensive Study by Type (EMR, EHR, MHealth, PHM, LIS, RIS, VNA, PACS, RCM, Analytics, EDI, SCM, HIE), Application (Hospital, Payor, Pharmacy, Ambulatory, Homecare), Deployme...
$ 3450
Hyaluronidase Power Injections Comprehensive Study by Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, Cosmetology), Distribution Channel (Hospitals, Retail Pharmacies, Online ...
$ 3650
Antibody Library Technology Comprehensive Study by Type (Phage Display, Ribosome Display, Yeast Display, Mammalian Cell Surface Display), End-User (Biopharmaceutical Companies, Contract Research Orga...
$ 3350
Endobronchial Ultrasound Biopsy Device Comprehensive Study by Type (EBUS-TBNA, Bronchoscopes and probes, Biopsy forceps and needles, Ultrasound processor and needles, Cytology brushes and spray cathe...
$ 3650